Tango Therapeutics, Inc.

Company-wide warning signs

These add points to every one of this company's trials.

Trials

• TNGXTango Therapeutics, Inc.

  0Calm

  TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients

  Not started yetPhase 1/2188 patientsMain results: Nov 2031
• TNGXTango Therapeutics, Inc.

  0Calm

  Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

  Signing up patientsPhase 1/2183 patientsMain results: Jun 2027
• TNGXTango Therapeutics, Inc.

  0Calm

  Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  Signing up patientsPhase 1/2191 patientsMain results: Mar 31, 2027
• TNGXTango Therapeutics, Inc.

  0Calm

  Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

  Signing up patientsPhase 1/2225 patientsMain results: Jun 2027
• TNGXTango Therapeutics, Inc.

  0Calm

  Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

  Running, no new patientsPhase 1/2126 patientsMain results: Sep 2026

Key executives leaving

From the last 12 months of the company's SEC reports.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

16 sales (0 not pre-planned) · 0 purchases

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

• Shared quarterly resultsNews report (8-K)Nov 9, 2026
• Quarterly reportQuarterly report (10-Q)Nov 9, 2026
• Shared information with investors; Other newsNews report (8-K)Oct 23, 2026
• Other newsNews report (8-K)Aug 11, 2026
• New shares being soldNew shares being sold (424B5)Aug 11, 2026

Money left